Regulators at the U.S. Food and Drug Administration (FDA) are reportedly weighing whether to sharply accelerate early-stage review steps for Eli Lilly and Co.’s (NYSE:LLY) experimental oral weight-loss treatment, orforglipron.

The initiative is part of the National Priority Voucher program, launched in June, which aims to streamline decisions for products tied to significant public-health or national-security needs.

Citing internal documents, Reuters noted that the FDA Commissioner's Office has urged staff to cut the standard 60-day filing check, used to confirm whether an application is complete, to as little as one week for Lilly's drug and others in a new expedited pathway.

Also Read: Eli Lilly’s Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain

Following internal pushback, the Commissioner's Office signaled it ...